SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today noted that the Society of Gynecologic Oncology (SGO) has issued new clinical practice statements surrounding hereditary cancer testing for patients with ovarian and endometrial cancer. The statements are consistent with the recently revised National Comprehensive Cancer Network (NCCN) guidelines and support broader access to genetic testing for patients with ovarian and endometrial cancer.
Help employers find you! Check out all the jobs and post your resume.
